NLS Pharmaceutics Ltd. Ordinary Shares
Symbol: NLSP (NASDAQ)
2.07
▲ (0.24%) 0.005
Company Description:
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
Key Stats
- Today's Open: $1.93
- Today's High: $2.115
- Today's Low: $1.94
- Today's Volume: 118.34K
- Yesterday Close: $2.06
- Yesterday High: $2.1
- Yesterday Low: $1.8
- Yesterday Volume: 314.11K
- Last Min Volume: 12
- Last Min High: $2.065
- Last Min Low: $2.065
- Last Min VWAP: $2.065
Company Profile
- Name: NLS Pharmaceutics Ltd. Ordinary Shares
- Website: https://www.nlspharma.com
- Listed Date: 2021-01-29
- Location: ,
- Market Status: Active
- CIK Number: 0001783036
- SIC Code:
- SIC description:
- Market Cap: $8.67M
- Round Lot: 100
- Outstanding Shares: 4.25M
- Asset Type: CS
RECENT FILINGS FOR NLSP
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-19 | 6-K | View |
| 2025-09-10 | 424B3 | View |
| 2025-09-10 | 6-K | View |
| 2025-09-09 | EFFECT | View |
| 2025-09-04 | 425 | View |
| 2025-09-04 | 6-K | View |
| 2025-09-03 | F-4/A | View |
| 2025-08-29 | 425 | View |
| 2025-08-29 | 6-K | View |
| 2025-08-25 | 6-K | View |
| 2025-08-06 | 6-K | View |
| 2025-07-29 | F-4/A | View |
| 2025-07-18 | F-4/A | View |
| 2025-07-18 | 425 | View |
| 2025-07-18 | 6-K | View |
| 2025-07-17 | 6-K | View |
| 2025-07-10 | D | View |
| 2025-07-01 | 6-K | View |
| 2025-07-01 | 425 | View |
| 2025-07-01 | 6-K | View |
Latest News on NLSP